

GLAXOSMITHKLINE PLC

Form 6-K

February 08, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 8 February 2019

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
    - a) Name Mr N Hirons
    - b) Position/status SVP, Global Ethics & Compliance
    - c) Initial notification/ amendment Initial notification
  2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
    - a) Name GlaxoSmithKline plc
    - b) LEI 5493000HZTVUYLO1D793
  3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

	American Depositary Shares ('ADSs')						
a) Description of the financial instrument	ISIN: US37733W1053						
b) Nature of the transaction	The exercise of options over 4,600 ADSs, granted on 17 February 2009 under the GlaxoSmithKline Share Option Plan.						
c) Price(s) and volume(s)	<table border="0" style="margin-left: 20px;"> <tr> <td style="text-align: right;">Price(s)</td> <td style="text-align: right;">Volume(s)</td> </tr> <tr> <td style="text-align: right;">\$33.4200</td> <td style="text-align: right;">1,608 (Non-Qualified Stock Option)</td> </tr> <tr> <td style="text-align: right;">\$33.4200</td> <td style="text-align: right;">2,992 (Incentive Stock Option)</td> </tr> </table>	Price(s)	Volume(s)	\$33.4200	1,608 (Non-Qualified Stock Option)	\$33.4200	2,992 (Incentive Stock Option)
Price(s)	Volume(s)						
\$33.4200	1,608 (Non-Qualified Stock Option)						
\$33.4200	2,992 (Incentive Stock Option)						
- Aggregated information
- |                             |            |
|-----------------------------|------------|
| d) Aggregated volume        | 4,600      |
| e) Date of the transaction  | 2019-02-07 |
| f) Place of the transaction | n/a        |

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics & Compliance
  - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

American Depositary Shares ('ADSs')

a) Description of the financial instrument ISIN: US37733W1053

b) Nature of the transaction

The sale of 4,600 ADSs, following the exercise of options granted on 17 February 2009 under the GlaxoSmithKline Share Option Plan.

c) Price(s) and volume(s)

Price(s) Volume(s)  
\$41.0800 1,608 (Non-Qualified Stock Option)  
\$41.0800 2,992 (Incentive Stock Option)

d) Aggregated information

Aggregated volume Price

4,600 \$41.0800

e) Date of the transaction

2019-02-07

f) Place of the transaction

New York Stock Exchange (XNYS)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 08, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc